Raymond James Financial Services Advisors Inc. Has $887,000 Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Raymond James Financial Services Advisors Inc. grew its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 42.9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 43,819 shares of the company’s stock after acquiring an additional 13,162 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Tarsus Pharmaceuticals were worth $887,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its stake in shares of Tarsus Pharmaceuticals by 0.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 139,151 shares of the company’s stock valued at $1,749,000 after buying an additional 600 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Tarsus Pharmaceuticals by 3.3% in the 1st quarter. Rhumbline Advisers now owns 28,518 shares of the company’s stock valued at $358,000 after buying an additional 924 shares in the last quarter. UBS Group AG raised its stake in shares of Tarsus Pharmaceuticals by 37.0% in the 1st quarter. UBS Group AG now owns 4,226 shares of the company’s stock valued at $71,000 after buying an additional 1,142 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Tarsus Pharmaceuticals by 13.0% in the 4th quarter. JPMorgan Chase & Co. now owns 11,351 shares of the company’s stock worth $167,000 after purchasing an additional 1,309 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of Tarsus Pharmaceuticals by 122.0% in the 2nd quarter. Royal Bank of Canada now owns 2,817 shares of the company’s stock worth $50,000 after purchasing an additional 1,548 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TARS shares. HC Wainwright upped their target price on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the stock a “neutral” rating in a report on Thursday, February 29th. Barclays upped their target price on shares of Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, February 28th. Lifesci Capital reaffirmed an “outperform” rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, December 26th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $59.00 target price (up previously from $55.00) on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $48.38.

Tarsus Pharmaceuticals Stock Down 3.4 %

Shares of NASDAQ:TARS opened at $34.94 on Tuesday. Tarsus Pharmaceuticals, Inc. has a 12 month low of $11.33 and a 12 month high of $40.40. The company’s 50-day moving average price is $33.58 and its two-hundred day moving average price is $23.97. The company has a quick ratio of 6.85, a current ratio of 6.93 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.20 billion, a P/E ratio of -7.53 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($1.31) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.06. The company had revenue of $13.08 million for the quarter, compared to the consensus estimate of $4.63 million. During the same period in the prior year, the company earned ($0.49) EPS. As a group, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -4.59 EPS for the current fiscal year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 4,436 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $135,741.60. Following the transaction, the general counsel now directly owns 40,951 shares in the company, valued at approximately $1,253,100.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 10,415 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $318,699.00. Following the transaction, the chief executive officer now directly owns 26,456 shares in the company, valued at approximately $809,553.60. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel Bryan Wahl sold 4,436 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $135,741.60. Following the transaction, the general counsel now owns 40,951 shares in the company, valued at $1,253,100.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,496 shares of company stock worth $749,578. Company insiders own 11.54% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.